Back to Search
Start Over
Current approaches used in treating COVID-19 from a molecular mechanisms and immune response perspective
- Source :
- Saudi Pharmaceutical Journal : SPJ, Saudi Pharmaceutical Journal, Saudi Pharmaceutical Journal, Vol 28, Iss 11, Pp 1333-1352 (2020)
- Publication Year :
- 2020
- Publisher :
- The Author(s). Published by Elsevier B.V. on behalf of King Saud University., 2020.
-
Abstract
- Coronavirus disease 2019 (COVID-19), which is caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was declared by the World Health Organization (WHO) as a global pandemic on March 11, 2020. SARS-CoV-2 targets the respiratory system, resulting in symptoms such as fever, headache, dry cough, dyspnea, and dizziness. These symptoms vary from person to person, ranging from mild to hypoxia with acute respiratory distress syndrome (ARDS) and sometimes death. Although not confirmed, phylogenetic analysis suggests that SARS-CoV-2 may have originated from bats; the intermediary facilitating its transfer from bats to humans is unknown. Owing to the rapid spread of infection and high number of deaths caused by SARS-CoV-2, most countries have enacted strict curfews and the practice of social distancing while awaiting the availability of effective U.S. Food and Drug Administration (FDA)-approved medications and/or vaccines. This review offers an overview of the various types of coronaviruses (CoVs), their targeted hosts and cellular receptors, a timeline of their emergence, and the roles of key elements of the immune system in fighting pathogen attacks, while focusing on SARS-CoV-2 and its genomic structure and pathogenesis. Furthermore, we review drugs targeting COVID-19 that are under investigation and in clinical trials, in addition to progress using mesenchymal stem cells to treat COVID-19. We conclude by reviewing the latest updates on COVID-19 vaccine development. Understanding the molecular mechanisms of how SARS-CoV-2 interacts with host cells and stimulates the immune response is extremely important, especially as scientists look for new strategies to guide their development of specific COVID-19 therapies and vaccines.
- Subjects :
- 0301 basic medicine
ARDS
ILCs, innate lymphoid cells
Pharmaceutical Science
Review
medicine.disease_cause
Bioinformatics
CoVs, coronaviruses
GVHD, graft versus host disease
APCs, antigen presenting cells
Pathogenesis
SLE, systemic lupus erythematosus
0302 clinical medicine
Pandemic
Medicine
030212 general & internal medicine
AHFS, American Hospital Formula Service
Coronavirus
ANGII, angiotensin II
HCoVs, human coronoaviruses
Coronavirus disease 2019 (COVID-19)
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
NKs, natural killer cells
ORFs, open reading frames
ACE2, angiotensin-converting enzyme 2
Pathophysiology
SARS-CoV-2, severe acute respiratory syndrome coronavirus 2
WHO, World Health Organization
03 medical and health sciences
Immune system
PAMPs, pathogen-associated molecular patterns
RdRp, RNA-dependent RNA polymerase
ARDS, acute respiratory distress syndrome
COVID-19, coronavirus disease
IFN-γ, interferon-gamma
Pharmacology
business.industry
SARS-CoV-2
lcsh:RM1-950
Investigational medications
medicine.disease
MERS-CoV, Middle East respiratory syndrome
Clinical trial
IBV, infectious bronchitis coronavirus
lcsh:Therapeutics. Pharmacology
030104 developmental biology
nsps, nonstructural proteins
TMPRSS2, transmembrane serine protease 2
business
Viral immune response
Subjects
Details
- Language :
- English
- ISSN :
- 22137475 and 13190164
- Database :
- OpenAIRE
- Journal :
- Saudi Pharmaceutical Journal : SPJ
- Accession number :
- edsair.doi.dedup.....a17e7ee501c0bd22429ec18bd065f733